Die Psoriasis-Krankheitskosten korrelieren mit der Schwere des klinischen Befundes und nicht mit der psychischen Krankheitslast

Abstract

Introduction Psoriasis is a chronic relapsing immune-mediated illness with a prevalence of 2% in Europe. Nearly 20% of the patients suffer from psoriasis at moderate to severe stage which needs a combined therapy of phototherapy and/or systemic therapy in addition to local therapeutics. Due to the incidence of severe forms, an elevated co-morbidity and the low age of manifestation the application of expensive and high-risk therapies are justified. Therefore, investigations for resource allocation to reach an optimal patient management become more and more important.